Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Aridis Enrolling CF Patients to Test AR-501 in Chronic Lung Infections Specific Sweat Test Better Detects Kalydeco’s Effects on CFTR Function, Study Suggests Aridis Enrolling CF Patients to Test AR-501 in Chronic Lung Infections Dec 14, 2018 08:00 am | Alice Melão Aridis Pharmaceuticals has enrolled the first healthy participant in its Phase 1/2a clinical trial to evaluate the antibacterial potential of its investigational candidate, AR-501 (gallium citrate), against chronic lung infections in patients with cystic fibrosis (CF). The study (NCT03669614) is expected to enroll approximately 48 healthy adult volunteers and 48 adult CF patients with chronic lung […] The post Aridis Enrolling CF Patients to Test AR-501 in Chronic Lung Infections appeared first on Cystic Fibrosis News Today. Read More Specific Sweat Test Better Detects Kalydeco’s Effects on CFTR Function, Study Suggests Dec 13, 2018 07:00 am | Ana Pena The effects of CFTR modulator therapies such as Kalydeco (ivacaftor) can be more reliably assessed using a test that specifically measures the sweating dependent on CFTR, called C-sweat rate, than using classic sweat tests or lung function measurements, a study reports. This kind of test was sensitive enough to reveal that Kalydeco also amplifies CFTR function in healthy […] The post Specific Sweat Test Better Detects Kalydeco’s Effects on CFTR Function, Study Suggests appeared first on Cystic Fibrosis News Today. Read More   Recent News Your CF Partner Can Help Make You Healthier Young CF Patients Deem Wrist-worn Devices Acceptable for Monitoring Physical Activity, Study Finds Higher Interleukin-7 Serum Levels Could be Biomarker for CF, Study Suggests People with Rare Diseases Are Humans, Not Commodities Handheld Wireless Home Spirometer Could Transform CF Monitoring, Pilot Study Suggests